Abbott (NYSE: ABT) has announced that the first patients have been treated with its Volt pulsed field ablation (PFA) system as part of a clinical study in Australia. The study is designed to evaluate the safety and effectiveness of the device in treating common cardiac arrhythmias such as atrial fibrillation (AFib). Used in conjunction with Abbott’s EnSite X cardiac mapping system, the Volt PFA system aims to achieve a high degree of accuracy and precision in ablating tissue that causes irregular heart signals, thereby reducing patient exposure to radiation.
The company plans to expand the trial to include markets across the Asia Pacific, Europe, and the US, demonstrating its commitment to advancing treatment options for cardiac arrhythmias globally.- Flcube.com
